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Introduction
It is well recognised that clinically relevant microorganisms
exist naturally as complex biofilm communities that differ sub-
stantially from their planktonic counterparts.[1, 2] Biofilm organ-
isms have a propensity for metabolic inactivity, and therefore
antimicrobial agents showing promise in planktonic culture
tend to be less efficacious against biofilms.[1] The biofilm mode
of growth has therefore been proposed as a mechanism for
the resistance of many chronic infections to antimicrobial
agents.[3]
The majority of in vitro treatment studies on biofilms focus
on single-species biofilms, whereas it is recognised that bio-
films in vivo are naturally polymicrobial, and can include mem-
bers of both bacterial and fungal genera. In polymicrobial in-
fections, microorganisms have been proposed to influence
each other either by exchange of molecules (sensing and sig-
nalling) or by physical contact (biofilm architecture), and this
might facilitate competitive, synergistic or neutral relation-
ships.[4, 5] In addition to a growing interest in multispecies bac-
terial biofilms,[6] there is also an emerging interest in the study
of polymicrobial fungal–bacterial biofilms. Cross-kingdom bio-
films containing Candida albicans[7] have been shown to be as-
sociated with clinical infections of both biotic and abiotic sur-
faces (e.g. cornea[8] and endotracheal tubes,[9] respectively).[10]
Although the role of C. albicans in polymicrobial biofilm forma-
tion is likely to be complex, recent work suggests that C. albi-
cans dramatically modifies the physical environment and 3D
architecture of polymicrobial biofilms[11] as well as influencing
interspecies protein expression[12] and extracellular DNA
(eDNA) release.[13]
Of particular concern in the current climate of antimicrobial
resistance are the findings, from drug susceptibility studies,
that fungal cells can modulate the action of antibiotics, and
that bacteria can influence antifungal activity.[14] Given the im-
portance of polymicrobial biofilms in vivo[10] and the increased
bacterial resistance to antibiotics observed in polymicrobial
biofilms containing C. albicans,[15] new treatments for cross-
kingdom biofilms are urgently required. The efficacy of the
Biofilms containing Candida albicans are responsible for a wide
variety of clinical infections. The protective effects of the bio-
film matrix, the low metabolic activity of microorganisms
within a biofilm and their high mutation rate, significantly en-
hance the resistance of biofilms to conventional antimicrobial
treatments. Peptoids are peptide-mimics that share many fea-
tures of host defence antimicrobial peptides but have in-
creased resistance to proteases and therefore have better sta-
bility in vivo. The activity of a library of peptoids was tested
against monospecies and polymicrobial bacterial/fungal bio-
films. Selected peptoids showed significant bactericidal and
fungicidal activity against the polymicrobial biofilms. This cou-
pled with low cytotoxicity suggests that peptoids could offer
a new option for the treatment of clinically relevant polymicro-
bial infections.
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innate immune system’s host defence peptides (HDPs) in pro-
viding the first line of defence against infection, and their
broad-spectrum action against both bacteria and fungi has
prompted us and others to investigate HDPs as templates for
the design of innovative therapeutics.[16–19] There is particular
need to identify new strategies for managing infection in order
to spare conventional systemic antimicrobial drugs. Despite
promising in vitro antimicrobial activities against a range of
bacterial and fungal pathogens, HDPs have been shown to be
susceptible to degradation by proteinases at wound and in-
flammatory sites,[20,21] thus potentially limiting their application
as anti-infectives. Despite the somewhat limited clinical success
of such peptides,[22] continuing advances in the design of pep-
tide mimics and the unmet clinical need for novel antimicrobi-
als have reinvigorated this research field.
Oligo N-substituted glycines (peptoids) are peptide ana-
logues that have many of the features of HDPs, with the ad-
vantage that they are resistant to proteinases[23] and therefore
offer a new avenue for antimicrobial therapeutics. Peptoids are
structural isomers of peptides, where the side-chain functional-
ity is attached to the nitrogen atom of the amide backbone
rather than the peptide a-carbon (Figure 1). Peptoids have
been shown to be efficacious against planktonic microorgan-
isms[24,25] and bacterial biofilms,[26] but their activities against
fungal biofilms and, in particular, polymicrobial bacterial–
fungal biofilms remain to be determined.
In this study we initially screened the efficacy of a linear
peptoid library against C. albicans, Staphylococcus aureus and
Escherichia coli monospecies biofilms, and then determined se-
lected peptoid efficacy against polymicrobial bacterial–fungal
biofilms (C. albicans–S. aureus and C. albicans–E. coli). We used
a crystal violet biofilm assay for the initial screening, and
adapted a novel quantitative PCR (qPCR) approach with propi-
dium monoazide (PMA)[27] for determining viable organism
numbers within the polymicrobial biofilms. The PMA-qPCR
assay is highly advantageous compared to traditional colony
forming unit (CFU) assays, in that it allows quantification of
viable but non-culturable (VBNC) microorganisms. The PMA-
qPCR assay is therefore particularly relevant for quantification
of microorganism within biofilms, which by their very nature
are likely to contain VBNC microorganisms. Additionally, the
crystal violet assay cannot distinguish between different spe-
cies within a polymicrobial biofilm, whereas qPCR can deter-
mine viable cell counts for individual specific pathogens within
polymicrobial biofilms, and therefore it offers a significant ad-
vantage in studies of this kind. To the best of our knowledge,
this is also the first time that peptoids have been proven to be
efficacious against fungal biofilms.
Results and Discussion
Peptoid design and synthesis
A library of 18 linear peptoids was synthesized to assess anti-
biofilm activity. The sequences were designed around an
NxNyNy subunit (Table 1), repeated two, three or four times
(six-, nine- and twelve-residue peptoids respectively), where Nx
is a positively charged lysine-type amine with various side-
chain lengths (Nah N-(6-aminohexyl)glycine, NLys N-(4-amino-
butyl)glycine and Nae N-(2-aminoethyl)glycine), and Ny is
either the chiral aromatic building block Nspe N-(S-phenyle-
thyl)glycine or the achiral Nphe N-benzylglycine. Peptoids were
synthesised with a repeat unit of three residues in order to
induce an amphipathic structure; the bulky Nphe and Nspe
monomers were included as these have been reported to en-
courage a helical structure that can lead to an improved anti-
microbial activity.[28–31] The 18 peptoids are classified into three
families (peptoids 1–6, 7–12 and 13–18) based on their posi-
tively charged building blocks (Nah, NLys or Nae). All peptoids
were synthesised manually on resin by the sub-monomer
method[32] on a shaker platform at room temperature (15 min
acylation steps and 15 min displacement steps). The library
was purified by RP-HPLC to greater than 95% purity (see the
Supporting Information for synthesis and characterisation).
Peptoid efficacy against single species biofilms
For the initial screening, the library was tested against single-
species biofilms of C. albicans, S. aureus and E. coli, by using
a crystal violet assay (Figure 2). The 18 peptoids had differing
antifungal and antibacterial activities against these single-spe-
cies biofilms, with 5, 7, and 17 amongst the most efficacious
from each of the three peptoid families for all three single-spe-
cies biofilms.
The peptoid library contained peptoids of three different
lengths: six-, nine- and twelve-residue peptoid analogues. In
agreement with previous studies,[24,30–31] the longest (twelve-
residue) peptoids tended to be most efficacious. They were
more active against C. albicans than nine-residue peptoids, and
the six-residue sequences were mostly inactive (compare 7
(dodecamer), 8 (nonamer) and 9 (hexamer)). For S. aureus, the
longer dodecamer sequences also had good activity, but inter-
estingly in most cases the nine-residue analogues caused a
greater reduction in biofilm mass; as found for C. albicans, the
six monomer peptoids were inactive. For E. coli, the longest
peptoids were the most active, except for those containing the
Nah monomer, where the nine-residue peptoids were most
active (i.e. , 13 and 17). Direct comparisons of sequence length
effects with previous reports[28,29] are complicated by the differ-
ing side-chains used and the resulting differences in charge/
length ratio.
The success of many linear antimicrobial peptides (AMPs) is
attributed to their overall positive charge, which helps them to
target prokaryotic cell membranes over mammalian cells,[16]
Therefore, the effect of different cationic monomers was inves-
tigated across the peptoid library. For sequences of the same
Figure 1. Representative structures of a-peptide and a-peptoid.
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length (i.e. , 12 residues), peptoids containing the shortest mo-
nomer (Nae) tended to be more active than the longer mono-
mer (e.g. , NLys, compare 1 and 7) for all species. On the
whole, peptoids containing Nah were less active than those
containing either Nae or NLys,[30] although 17 was an excep-
tion. The reduced activity of the NahNyNy peptoids might
stem from the greater flexibility of the longer aminohexane
chain.
The peptoid library was designed to include sequences con-
taining either the chiral Nspe or the achiral Nphe monomer, in
order to determine the effect of sequence chirality on anti-bio-
film activity. A range of chiral and achiral peptoid analogues
were tested. Overall, sequences containing Nspe were more ef-
ficacious than their achiral analogues (compare 1 and 4) across
all three biofilm species. However, for peptoids containing the
shortest Nae monomer, there was little difference in activity
between chiral and achiral peptoids (10–12 and 7–9, respec-
tively) against S. aureus or C. albicans. The differences in activi-
ty for chiral and achiral members of the entire peptoid library
were even less pronounced against E. coli.
The entire peptoid library was also screened against two
representative mammalian cell lines, HaCaT and HepG2, to de-
termine if the sequences were selective for the bacteria and
fungi tested (Supporting Information). The majority of the pep-
toids showed ED50 values above100 mm against both, this indi-
cating minimal cytotoxicity on model human keratinocyte and
endothelial cells. The only sequences that showed toxicity
were the 12-residue peptoids containing the chiral Nspe mo-
nomer (4, 10 and 16).
Although it is generally acknowledged that peptoids are in-
herently resistant to proteolysis,[23,33] we compared the tryptic
digestion profile of 7 against the naturally occurring alpha heli-
cal peptide LL-37. Peptoid 7 showed no degradation following
treatment with trypsin for 24 h, whereas LL-37 was degraded
to peptide fragments (Supporting Information).
Peptoid efficacy against polymicrobial biofilms
Although widely used in biofilm assays, the crystal violet assay
detects both live and dead organisms, in addition to matrix
Table 1. Peptoid library divided into three families (1–6 ; 7–12 and 13–18) on the basis of their building blocks.
Peptoid Sequence Nx Ny
1 (NLysNpheNphe)4
2 (NLysNpheNphe)3
3 (NLysNpheNphe)2
4 (NLysNspeNspe)4
5 (NLysNspeNspe)3
6 (NLysNspeNspe)2
7 (NaeNpheNphe)4
8 (NaeNpheNphe)3
9 (NaeNpheNphe)2
10 (NaeNspeNspe)4
11 (NaeNspeNspe)3
12 (NaeNspeNspe)2
13 (NahNpheNphe)4
14 (NahNpheNphe)3
15 (NahNpheNphe)2
16 (NahNspeNspe)4
17 (NahNspeNspe)3
18 (NahNspeNspe)2
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components. Conventional CFU assays have been reported to
underestimate live cell numbers because they cannot quantify
VBNC cells.[34,35] Furthermore, microorganisms have been
shown to enter the VBNC sate when exposed to antibiotic
treatment.[36] Therefore the use of non-cultivation-based assays
to evaluate the efficacy of novel antimicrobials is particularly
appealing for studying microorganisms in biofilm form. In this
study, we developed a novel PCR method to selectively and
quantitatively determine fungicidal and bactericidal activity
against both monospecies and polymicrobial biofilms.
PMA is a photo-reactive dye with a high affinity for DNA,
with which it forms a covalent linkage upon exposure to in-
tense visible light. The use of PMA allows qPCR quantification
of DNA from living cells only, because PMA binds covalently to
DNA that lacks the protection of a cell membrane in viable
microorganism[27] and prevents DNA amplification by qPCR. As
PMA discriminates between live and dead cells on the basis of
membrane integrity,[37] its addition to the qPCR protocol is par-
ticularly suitable for quantifying the efficacy of membrane-tar-
geting agents such as peptoids.
Three peptoids (5 (NLysNspeNspe)3, 7 (NaeNpheNphe)4, and
17 (NahNspeNspe)3) were chosen, as they were some of the
most active peptoids in the single-species crystal violet assays
and showed negligible toxicity to the two mammalian cell
lines. All monospecies biofilms treated with these peptoids
showed significant reduction in cell number by the novel PMA-
qPCR method, thus indicating strong bactericidal and fungici-
dal activity (Figure 3). The three peptoids had a similar efficacy
against S. aureus : cell numbers reduced by approximately two
orders of magnitude, with 5 and 7 showing even better effects
(reduction by over four orders of magnitude against this mi-
croorganism). In agreement with the crystal violet assay results,
the Nah-containing peptoid 17 did not perform quite as well
against C. albicans, although it still caused a significant reduc-
tion in the fungal biofilm. Conversely, in the E. coli monospe-
cies biofilms, 17 was the most effective.
Peptoids 5, 7 and 17 were also tested at 100 mm against
mixed-species biofilms of C. albicans and either S. aureus or
E. coli. (Figure 4). In the latter, the C. albicans cell number re-
duced more than for E. coli. The Nah-containing peptoid (17)
was the most active. In the former, cell numbers were reduced
more for bacteria than fungi. Peptoid 5 was better able to
reduce the cell count of S. aureus, and 7 showed the greatest
reduction in C. albicans. C. albicans appeared to be less suscep-
tible to 17 when in a biofilm with S. aureus, but this did not
appear to be the case with E. coli. As there has been very limit-
ed work on peptoid efficacy in polymicrobial biofilms, it re-
mains to be determined if this is a unique phenomenon.
In order to look in more detail at the activities of 5, 7 and
17, cross-kingdom biofilms were treated at 10–100 mm and as-
sessed by PMA-qPCR (Supporting Information). In the mixed-
species biofilms, all three peptoids significantly reduced the
cell numbers of S. aureus by almost 100%, even at 10 mm. Re-
duction in cell viability for E. coli or C. albicans was less effica-
cious at 10 mm, but considerable reductions were seen at 25
and 50 mm. For all three species in the cross-kingdom biofilms,
17 showed the greatest reduction in cell numbers.
Effect of peptoids on microbial cell membranes
The majority of AMPs exert their antimicrobial effects by dis-
ruption of cellular membranes. It is thought that as linear anti-
microbial peptoids (such as those studied here) are structurally
very similar to this class of AMP, they might also exert their
biological mode of action by cell membrane disruption. How-
ever, only a few studies have provided experimental evidence
to support this hypothesis.[38–42]
In order to help elucidate the mode of action of the pep-
toids studied in the qPCR experiments and to verify the use of
the PMA-qPCR assay (depends on the integrity of the cell
Figure 2. Efficacy of a family of 18 peptoids against A) C. albicans, B) S. au-
reus, and C) E. coli monospecies biofilms determined by a crystal violet assay.
Biofilms were treated with peptoid (100 mm) or untreated. The results
(meanSD, n=3) are plotted as percent biomass relative to untreated cells.
Statistical analysis was determined by one-way ANOVA followed by Tukey’s
post hoc correction for multiple comparisons (ns: p>0.05, *p<0.05, **p<
0.01, ***p<0.001, ****p<0.0001).
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membrane), membrane permeabilisation assays were per-
formed with 100 mm 5, 7 and 17 against C. albicans, S. aureus
and E. coli. These assays used the dye SYTOX Green, which is
able to bind nucleic acids but is impermeable to living eukary-
otic and prokaryotic cells. Therefore, this dye is routinely used
to assess the integrity of cell membranes. If a microbial cell
membrane has been compromised, for example by treatment
with a peptoid, SYTOX Green can bind to the cellular nucleic
acids. This association increases the fluorescence of the dye
and renders cells with compromised membranes as brightly
green fluorescent.[43,44] The propensities of 5, 7 and 17 to per-
meabilise cell membranes was assessed (Figure 5). The data
clearly show large increases in fluorescence, thus demonstrat-
ing that all three peptoids caused cell-membrane permeabilisa-
tion in C. albicans, E. coli and S. aureus.
The peptoids with the greatest antimicrobial effect against
single-species biofilms (Figure 3) also caused the greatest
membrane permeabilisation in the SYTOX Green assay
(Figure 5). For example, against C. albicans, 5 caused the great-
est reduction in cell number and the greatest increase in fluo-
rescence. The results strongly support that the microbial action
of 5, 7 and 17 is membrane disruption, but additional action
by a secondary intracellular target cannot be ruled out.
Figure 3. PMA-qPCR quantification of cell number following peptoid treatment of monospecies biofilms of A) C. albicans, B) S. aureus and C) E. coli treated
with 100 mm 5, 7 and 17 (****p<0.0001; one-way ANOVA followed by Tukey’s post hoc correction for multiple comparisons, meanSD, n=3).
Figure 4. PMA-qPCR quantification of cell number following treatment by 100 mm 5, 7 and 17 of polymicrobial biofilms of C. albicans with either S. aureus or
E. coli : A) C. albicans and B) S. aureus within the same biofilm, and C) C. albicans and D) E. coli within the same biofilm (one-way ANOVA followed by Tukey’s
post hoc correction for multiple comparisons, **p<0.01, ****p<0.0001; meanSD, n=3).
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Conclusion
Peptoids, an emerging class of peptidomimetics that have pre-
viously been tested principally for their activity against bacteria
in planktonic and biofilm form,[26,28,29, 45,46] were shown for the
first time to be efficacious against C. albicans biofilms and
against cross-kingdom polymicrobial biofilms. We have shown
the in vitro effectiveness of a peptoid library against both
single species C. albicans, S. aureus and E. coli biofilms and we
also report their excellent fungicidal and bactericidal activity in
polymicrobial biofilms by using PMA-modified qPCR. SYTOX
Green membrane-leakage assays identified that the cell mem-
branes of C. albicans, S. aureus and E. coli are the likely targets
through which the peptoids screened exert their antimicrobial
mode of action.
The peptoid library showed similar activity patterns across
the three species tested by crystal violet assay, that is, peptoids
that were active at some level against one species also tended
to be active against the others. However, these peptoids gen-
erally caused the greatest reduction in biofilm mass against
S. aureus, followed by C. albicans, with E. coli biofilms showing
the least reduction in biofilm mass following peptoid treat-
ment. Planktonic E. coli has also proven more difficult to treat
than Gram-positive bacteria in previous studies on peptoid effi-
cacy.[24,25]
From the qPCR data, 17 (NahNspeNspe)3 was identified as
the most promising candidate. This peptoid has low toxicity,
significant activity against S. aureus in a mixed-species biofilm
with C. albicans at 10 mm, and it also shows good activity
against both species in the C. albicans and E. coli biofilm at
higher concentrations.
Finally, peptoids potentially have an advantage over conven-
tional antifungals and antibacterials in that their proposed bio-
logical mode of action (disruption of cellular membranes)
limits the emergence of resistance as this would require the
fungi and bacteria to undertake the arduous task of altering
cellular membrane composition. Furthermore, their enhanced
stability towards proteolytic degradation means that peptoids,
rather than peptides, might represent a more realistic class of
molecule for the development of new therapeutics.
Experimental Section
Peptoid synthesis: Details can be found in the Supporting Infor-
mation. Fmoc-protected Rink amide resin (typically 100 mg,
0.1 mmol; 0.6–0.8 mmolg1 loading) was swollen in DMF (at least
1 h at room temperature, overnight preferred) in a 20 mL poly-
propylene syringe fitted with two polyethylene frits (Crawford Sci-
entific). The resin was deprotected with piperidine (20% v/v in
DMF, 220 min) and washed with DMF (32 mL). The resin was
treated with bromoacetic acid (8 equiv with respect to the resin,
2m in DMF) and DIC (8 equiv, 2m in DMF) for 15 min at 50 8C on
a heated shaker at 400 rpm. The resin was washed with DMF (3
2 mL), before the desired amine sub-monomer was added (4 equiv,
1m in DMF) and allowed to react for 15 min at 50 8C on the shaker.
The resin was again washed with DMF (32 mL), and the bromoa-
cetylation and amine displacement steps were repeated until the
final sub-monomer had been added (i.e. desired peptoid sequence
obtained). The resin was shrunk in diethyl ether (3 mL), and final
cleavage from resin was achieved by using a TFA cleavage cocktail
(4 mL, TFA/TIPS/H2O, 95:2.5:2.5) on the shaker (400 rpm) for
60 min. The resin was removed by filtration, and the cleavage cock-
tail was removed in vacuo. The crude product was precipitated in
diethyl ether (30 mL), and the precipitate was retrieved by centrifu-
gation (447g, 15 min). The ether phase was decanted, and the
crude product was dissolved in a mixture of acidified H2O and
MeCN and lyophilised before purification by RP-HPLC and subse-
quent characterisation (see the Supporting Information for equip-
ment, procedures and data).
Peptoid cytotoxicity studies: All 18 peptoids were tested for cyto-
toxicity against HepG2 epithelial (Sigma–Aldrich) and HaCaT kerati-
nocyte (ThermoFisher) cell lines, Cytotoxicity analyses were per-
formed in Costar 96-well plates (Thermo Fisher Scientific) with ala-
marBlue (Invitrogen/Thermo Fisher Scientific) for cell viability de-
tection as described by the manufacturer. HepG2 and HaCaT cells
were grown at 37 8C under CO2 (5%) in DMEM (high glucose) sup-
plemented with heat-inactivated foetal bovine sera (FBS, 10%; Bio-
sera, Uckfield, UK) and penicillin/streptomycin (1%). Cells were
counted in a Neubauer Improved Haemocytometer. HepG2 or
Figure 5. Propensity for 5, 7 and 17 to permeabilise the microbial membranes of A) C. albicans, B) E. coli and C) S. aureus, as determined by a SYTOX Green
assay. The data were compared with untreated cells, and the results (meanSD, n=3) were analysed by ANOVA followed by Tukey’s post hoc correction for
multiple comparisons (****p<0.0001). Cells permeabilised by heat treatment were used as positive controls.
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HaCaT cells were seeded 24 h prior to treatment in 96-well plates
(2104 cells per well in 100 mL). After 24 h, cells were incubated in
triplicate with a dilution series of compound (2–100 mm from 5 mm
stock solutions in DMSO) in the medium (50 mL) for 1 h. An aliquot
(40 mL) was removed from each well, before the addition of
medium (90 mL) followed by incubation for 24 h (37 8C, 5% CO2).
Then, alamarBlue (10 mL) was added to each well before incubation
(2 h for Hep G2, 1 h for HaCaT) prior to assessing cell viability in
a fluorescent plate reader (Biotek, Winooski, VT; lex=560 nm, lem=
600 nm). All data were measured in triplicate on a minimum of
two occasions.
Proteolytic stability studies: Peptoid stability was confirmed by
comparing the tryptic digestion of 7 with LL-37 (Innovagen AB,
Lund, Sweden). Stock solutions (5 mgmL1) of 7 and LL-37 were
prepared, and samples (7.5 mL) were incubated with trypsin
(0.5 mgmL1) and incubation buffer (37.5 mL, Tris·HCl (50 mm,
pH 7.8) containing CaCl2 (9 mm)). After 0 h (for mass spectrometric
verification) or 24 h, the reaction mixture was acidified by addition
of TFA (10%, 50 mL) to denature the enzyme and stop enzyme ac-
tivity. The samples were air-dried and then reconstituted in aceto-
nitrile/water/TFA (50 mL, 40:59.5:0.5, v/v/v), and an aliquot (1 mL)
was placed onto a stainless steel MALDI target. Samples were cov-
ered immediately with matrix (1 mL, a-cyano-4-hydroxycinnamic
acid (53 mm in acetonitrile/water/TFA, 70:29.98:0.02, v/v/v)).
MALDI-TOF MS was performed on a linear TOF Voyager DE-mass
spectrometer (PerSeptive Biosystems, Farmingham, MA, USA). The
samples were analysed in positive detection mode, and internal
mass calibration with known standards established the mass accu-
racy to 0.1%. Fifty laser scans were averaged for each sample,
and variable laser intensity was used to ensure the most represen-
tative mass spectra for the wells.
Microorganism strains and growth conditions: C. albicans (NCTC
3179) was subcultured aerobically on Sabouraud agar plates, pre-
pared by using Sabouraud dextrose powder and agar (Oxoid, Ther-
moFisher) and propagated in yeast peptone dextrose broth. E. coli
(ATCC 29522) and S. aureus (NCTC 6571) were grown on blood
agar plates (Fanin, Dublin, Ireland) and propagated in brain heart
infusion (BHI) broth (Oxoid, ThermoFisher).
Preparation and treatment of single-species biofilms: Overnight
cultures of C. albicans were washed and resuspended (1.0
106 cells per mL) in RPMI-1640 (Sigma–Aldrich). Overnight cultures
of S. aureus or E. coli were washed and resuspended (5.0106 cells
per mL) in BHI broth. Samples (100 mL) were added to microtitre
plate wells (Thermo Fisher Scientific), and a biofilm was allowed to
form for 4 h. Wells were washed with PBS (3200 mL) to facilitate
removal of planktonic cells, and the biofilms were then treated
with 1–18 (100 mm in the appropriate medium). Plates were incu-
bated for a further 24 h to allow biofilm maturation. After removal
of planktonic cells by washing, biofilms were quantified by the
crystal violet assay or by PMA-qPCR.
Preparation and treatment of polymicrobial biofilms: Overnight
cultures of C. albicans were prepared in microtitre plates as above,
and allowed to adhere for 4 h to facilitate initial biofilm formation.
Planktonic C. albicans cells were removed as above before the ad-
dition of S. aureus or E. coli (100 mL, 5.0106 cells per mL). Bacteria
were allowed to adhere to the C. albicans biofilms for 4 h to facili-
tate polymicrobial biofilm formation. Following a washing step, the
biofilms were then treated with peptoid (10–100 mm), and incubat-
ed for a further 24 h to allow biofilm maturation. Wells were
washed as above, and the polymicrobial biofilms were quantified
by PMA-modified qPCR.
Biofilm quantification by crystal violet assay: Washed biofilms
were fixed with methanol (100 mL) for 10 min. Following removal
of methanol, the wells were air dried and stained with crystal
violet solution (Clin-Tech, Guildford, UK) for 20 min at room tem-
perature. Excess stain was removed by washing, then the plate
was air-dried and bound crystal violet was re-solubilised in acetic
acid (33%, 160 mL) prior to reading at 570 nm in a GENios microti-
tre plate reader (Tecan, Zrich, Switzerland).
Biofilm quantification by PMA-modified qPCR: In order to deter-
mine the bactericidal and fungicidal activity of peptoids against
single-species and polymicrobial biofilms, the biofilms were de-
tached from the microtitre plate wells prior to quantification. The
wells were washed as above, then BHI broth (100 mL) was added
and the plate was sealed. Biofilm detachment was achieved by
sonication for 5 min in an ultrasonic bath (Dawe, Hayes, Middlesex,
UK). The remaining cells were then collected in BHI (80 mL). PMA
(20 mL, 2 mm in broth;[47] Biotium, Fremont, CA) was added to the
biofilm suspensions (180 mL) and incubated (37 8C, 5 min) prior to
photoactivation with a broad-spectrum LED flood light (60 LED,
0.1 W) placed 15 cm from the tubes (mixed by inversion during the
20 min photoactivation step).[48] DNA was extracted by using a mi-
croLYSIS-Plus kit (Microzone, Haywards Heath, UK), and qPCR was
performed in a Mx3005P qPCR System (Agilent Technologies).[49–51]
See the Tables in the Supporting Information.
Generation of standard curves for PMA-qPCR: For quantification
of C. albicans, S. aureus and E. coli in single-species and polymicro-
bial biofilms, DNA standards were prepared by extraction of DNA
from planktonic organisms with the microLYSIS-Plus kit and purifi-
cation with a DNeasy kit (Qiagen). DNA standards (101–106 cells)
were used in PMA-qPCR assays to generate standard curves from
which the numbers of living organisms within the biofilms could
be determined.
SYTOX Green assay: Briefly, mid-log-phase microorganism cultures
were adjusted to the appropriate concentration (OD600=0.7 for
S. aureus and E. coli, OD600=2.0 for C. albicans). A microorganism
suspension in Mueller Hinton broth (MHB,50 mL) was added to
each well of a 96-well black flat-bottomed plate. Peptoids (50 mL,
final 100 mm) were added to the wells then SYTOX Green (Thermo-
Fisher; final 5 mm) was added. The plate was covered, protected
from light and incubated for 2 h at 37 8C. Heat-treated microorgan-
isms (99 8C for 10 min to permeabilise membranes) served as posi-
tive controls. Bacteria without peptoid were negative controls.
Wells containing only SYTOX Green were included to quantify
background fluorescence. Wells containing SYTOX Green and pep-
toid were included to confirm no interaction between the SYTOX
Green and peptoid leading to non-specific fluorescence. The plate
was read on a SpectraMax Gemini X fluorimeter (Molecular Devi-
ces, Sunnyvale, CA; lex=480 nm, lem=530 nm).
Statistical analysis: The susceptibility of C. albicans, S. aureus and
E. coli in both single-species and polymicrobial biofilms to novel
peptoids was determined by biofilm inhibition assays. All data
from three independent experiments were subject to statistical
analysis by one-way ANOVA followed by Tukey’s post hoc correc-
tion for multiple comparisons.
Acknowledgements
This work was supported by Queen’s University Belfast (Interna-
tional PhD studentship Y.L.) ; The Biochemical Society’s Eric Reid
Fund for Methodology; The Health and Social Care Research and
ChemBioChem 2016, 17, 1 – 9 www.chembiochem.org  2016 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim7 &
These are not the final page numbers! 
Full Papers
Development Office, Northern Ireland; The Engineering and Phys-
ical Sciences Research Council (PhD studentship H.L.B.) and The
Swiss National Science Foundation (G.A.E.).
Keywords: antibacterial · antibiotics · antiproliferation · cross
kingdom · peptoid · quantification
[1] R. M. Donlan, J. W. Costerton, Clin. Microbiol. Rev. 2002, 15, 167–193.
[2] H.-C. Flemming, J. Wingender, Nat. Rev. Microbiol. 2010, 8, 623–633.
[3] N. Høiby, T. Bjarnsholt, M. Givskov, S. Molin, O. Ciofu, Int. J. Antimicrob.
Agents 2010, 35, 322–332.
[4] K. A. Brogden, J. M. Guthmiller, C. E. Taylor, Lancet 2005, 365, 253–255.
[5] F. L. Short, S. L. Murdoch, R. P. Ryan, Trends Microbiol. 2014, 22, 508–
516.
[6] S. Elias, E. Banin, FEMS Microbiol. Rev. 2012, 36, 990–1004.
[7] M. E. Shirtliff, B. M. Peters, M. A. Jabra-Rizk, FEMS Microbiol. Lett. 2009,
299, 1–8.
[8] N. C. S. Lim, D. K. A. Lim, M. Ray, Eye Contact Lens 2013, 39, 348–354.
[9] S. Cairns, J. G. Thomas, S. J. Hooper, M. P. Wise, P. J. Frost, M. J. Wilson,
M. A. O. Lewis, D. W. Williams, PLoS One 2011, 6, e14759.
[10] M. M. Harriott, M. C. Noverr, Trends Microbiol. 2011, 19, 557–563.
[11] M. L. Falsetta, M. I. Klein, P. M. Colonne, K. Scott-Anne, S. Gregoire, C.-H.
Pai, M. Gonzalez-Begne, G. Watson, D. J. Krysan, W. H. Bowen, H. Koo,
Infect. Immun. 2014, 82, 1968–1981.
[12] B. M. Peters, M. A. Jabra-Rizk, M. A. Scheper J. G. Leid, J. W. Costerton,
M. E. Shirtliff, FEMS Immunol. Med. Microbiol. 2010, 59, 493–503.
[13] M. Pammi, R. Liang, J. Hicks, T.-A. Mistretta, J. Versalovic, BMC Microbiol.
2013, 13, e257.
[14] H. F. Jenkinson, L. J. Douglas in Polymicrobial Diseases (Eds. : K. A. Brog-
den, J. M. Guthmiller), ASM Press, Washington, DC, 2002, p. 357–373.
[15] M. M. Harriott, M. C. Noverr, Antimicrob. Agents Chemother. 2010, 54,
3746–3755.
[16] R. E. W. Hancock, H.-G. Sahl, Nat. Biotechnol. 2006, 24, 1551–1557.
[17] F. T. Lundy, J. Nelson, D. Lockhart, B. Greer, P. Harriott, J. J. Marley, Mol.
Immunol. 2008, 45, 190–193.
[18] J. He, M. H. Anderson, W. Shi, R. Eckert, Int. J. Antimicrob. Agents 2009,
33, 532–537.
[19] N. K. Brogden, K. A. Brogden, Int. J. Antimicrob. Agents 2011, 38, 217–
225.
[20] M. T. C. McCrudden, D. T. F. McLean, M. Zhou, J. Shaw, G. J. Linden, C. R.
Irwin, F. T. Lundy, Int. J. Pept. Res. Ther. 2014, 20, 457–464.
[21] M. T. C. McCrudden, D. F. Orr, Y. Yu, W. A. Coulter, G. Manning, C. R.
Irwin, F. T. Lundy, J. Clin. Periodontol. 2013, 40, 933–941.
[22] L. Zhang, T. J. Falla, Expert Opin. Pharmacother. 2006, 7, 653–663.
[23] J. Seo, G. Ren, H. Liu, Z. Miao, M. Park, Y. Wang, T. M. Miller, A. E. Barron,
Z. Cheng, Bioconjugate Chem. 2012, 23, 1069–1079.
[24] T. S. Ryge, N. Frimodt-Moller, P. R. Hansen, Chemotherapy 2008, 54, 152–
156.
[25] B. Mojsoska, R. N. Zuckermann, H. Jenssen, Antimicrob. Agents Chemo-
ther. 2015, 59, 4112–4120.
[26] R. Kapoor, M. W. Wadman, M. T. Dohm, A. M. Czyzewski, A. M. Spor-
mann, A. E. Barron, Antimicrob. Agents Chemother. 2011, 55, 3054–3057.
[27] S. Tavernier, T. Coenye, Peer J. 2015, 3, e787.
[28] N. P. Chongsiriwatana, J. A. Patch, A. M. Czyzewski, M. T. Dohm, A. Ivan-
kin, D. Gidalevitz, R. N. Zuckermann, A. E. Barron, Proc. Natl. Acad. Sci.
USA 2008, 105, 2794–2799.
[29] R. Kapoor, P. R. Eimerman, J. W. Hardy, J. D. Cirillo, C. H. Contag, A. E.
Barron, Antimicrob. Agents Chemother. 2011, 55, 3058–3062.
[30] G. A. Eggimann, H. L. Bolt, P. W. Denny, S. L. Cobb, ChemMedChem 2015,
10, 233–237.
[31] H. L. Bolt, G. A. Eggimann, P. W. Denny, S. L. Cobb, Med. Chem. Commun.
2016, 7, 799–805.
[32] R. N. Zuckermann, J. M. Kerr, S. B. H. Kent, W. H. Moos, J. Am. Chem. Soc.
1992, 114, 10646–10647.
[33] R. N. Zuckermann, T. Kodadek, Curr. Opin. Mol. Ther. 2009, 11, 299–307.
[34] R. J. Rezende Delgado, T. H. Gasparoto, C. R. Sipert, C. Ramos Pinheiro, I.
Gomes de Moraes, R. Brand¼o Garcia, M. A. H. Duarte, C. Monteiro Bra-
mante, S. Aparecido Torres, G. Pompermaier Garlet, A. P. Campanelli, N.
Bernardineli, Int. J. Oral Sci. 2013, 5, 32–36.
[35] L. Li, N. Mendis, H. Trigui, J. D. Oliver, S. P. Faucher, Front. Microbiol.
2014, 5, 258.
[36] S. Pasquaroli, G. Zandri, C. Vignaroli, C. Vuotto, G. Donelli, F. Biavasco, J.
Antimicrob. Chemother. 2013, 68, 1812–1817.
[37] A. Nocker, A. K. Camper, FEMS Microbiol. Lett. 2009, 291, 137–142.
[38] F. Guilhelmelli, N. Vilela, P. Albuquerque, L. da S. Derengowski, I. Silva-
Pereira, C. M. Kyaw, Front. Microbiol. 2013, 4, 353.
[39] H. Jenssen, P. Hamill, R. E. W. Hancock, Clin. Microbiol. Rev. 2006, 19,
491–511.
[40] S. K. Straus, R. E. W. Hancock, Biochim. Biophys. Acta Biomembr. 2006,
1758, 1215–1223.
[41] M. Torrent, D. Pulido, L. Rivas, D. Andreu, Curr. Drug Targets 2012, 13,
1138–1147.
[42] M. R. Yeaman, N. Y. Yount, Pharmacol. Rev. 2003, 55, 27–55.
[43] B. L. Roth, M. Poot, S. T. Yue P. J. Millard, Appl. Environ. Microbiol. 1997,
63, 2421–2431.
[44] D. T. F. McLean, F. T. Lundy, D. J. Timson, Biochimie 2013, 95, 875–880.
[45] C. Ghosh, G. B. Manjunath, P. Akkapeddi, V. Yarlagadda, J. Hoque,
D. S. S. M. Uppo, M. M. Konai, J. Haldar, J. Med. Chem. 2014, 57, 1428–
1436.
[46] M. L. Huang, S. B. Y. Shin, M. A. Benson, V. J. Torres, K. Kirshenbaum,
ChemMedChem 2012, 7, 114–122.
[47] C. G. Pierce, P. Uppuluri, A. R. Tristan, F. L. Wormley, Jr. , E. Mowat, G.
Ramage, J. L. Lopez-Ribot, Nat. Protoc. 2008, 3, 1494–1500.
[48] J. K. van Frankenhuyzen, J. T. Trevors, C. A. Flemming, H. Lee, M. B.
Habash, J. Ind. Microbiol. Biotechnol. 2013, 40, 1251–1261.
[49] C. Schabereiter-Gurtner, B. Selitsch, M. L. Rotter, A. M. Hirschl, B. Willing-
er, J. Clin. Microbiol. 2007, 45, 906–914.
[50] R. McDonald, N. A. Antonishyn, T. Hansen, L. A. Snook, E. Nagle, M. R.
Mulvey, P. N. Levett, G. B. Horsman, J. Clin. Microbiol. 2005, 43, 6147–
6149.
[51] D. H. Lee, J. E. Bae, J. H. Lee, J. S. Shin, I. S. Kim, J. Microbiol. Biotechnol.
2010, 20, 1463–1470.
Manuscript received: July 6, 2016
Accepted Article published: November 7, 2016
Final Article published: && &&, 0000
ChemBioChem 2016, 17, 1 – 9 www.chembiochem.org  2016 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim8&
 These are not the final page numbers!
Full Papers
FULL PAPERS
Y. Luo, H. L. Bolt, G. A. Eggimann,
D. F. McAuley, R. McMullan, T. Curran,
M. Zhou, P. C. A. B. Jahoda, S. L. Cobb,*
F. T. Lundy*
&& –&&
Peptoid Efficacy against Polymicrobial
Biofilms Determined by Using
Propidium Monoazide-Modified
Quantitative PCR
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microbial peptides but have increased
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a library of such peptoids and showed
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crobial biofilms, as quantified by a novel
PMA-qPCR assay.
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